MedTrace Logo

Handling Medium for ICSI With Ionomycin and Latrunculin A

NCT03678610 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 700

Last updated 2019-05-07

No results posted yet for this study

Summary

Using Latrunculin A and Ionomycin would improve the outcome of ICSI if the handling medium during the ICSI procedure has them.

Conditions

Interventions

OTHER

Doing ICSI I a medium supplemented with Ionomycin and Latrunculin A

Ionomycin and Latrunculin A would activate oocyte during ICSI along with cytoskeleton stabilization for a favourable outcomes

Sponsors & Collaborators

  • Banoon IVF Center

    collaborator OTHER

  • Qena Fertility Center

    collaborator UNKNOWN

  • Ibn Sina Hospital

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-25
Primary Completion
2019-05-01
Completion
2019-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03678610 on ClinicalTrials.gov